Gemer V 1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated for extended release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The synergistic action of these three agents addresses multiple pathophysiological defects in type 2 diabetes, offering comprehensive glycemic management. Gemer V 1 Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The extended-release formulation ensures sustained plasma concentrations, enhancing patient compliance through reduced dosing frequency. Caution is advised in patients with renal or hepatic impairment, and monitoring for hypoglycemia is essential due to the insulin secretagogue effect of Glimepiride. This combination should be used under medical supervision, with regular monitoring of blood glucose levels to minimize adverse effects and optimize therapeutic outcomes.